Cargando…
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/ https://www.ncbi.nlm.nih.gov/pubmed/30514331 http://dx.doi.org/10.1186/s13046-018-0954-5 |
_version_ | 1783378681450725376 |
---|---|
author | Caiola, Elisa Falcetta, Francesca Giordano, Silvia Marabese, Mirko Garassino, Marina C. Broggini, Massimo Pastorelli, Roberta Brunelli, Laura |
author_facet | Caiola, Elisa Falcetta, Francesca Giordano, Silvia Marabese, Mirko Garassino, Marina C. Broggini, Massimo Pastorelli, Roberta Brunelli, Laura |
author_sort | Caiola, Elisa |
collection | PubMed |
description | BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also have deletions or inactivating mutations in the serine/threonine kinase 11 (LKB1) gene. Loss of LKB1 on a KRAS-mutant background may represent a significant source of heterogeneity contributing to poor response to therapy. METHODS: Here, we employed an integrated multilevel proteomics, metabolomics and functional in-vitro approach in NSCLC H1299 isogenic cells to define their metabolic state associated with the presence of different genetic background. Protein levels were obtained by label free and single reaction monitoring (SRM)-based proteomics. The metabolic state was studied coupling targeted and untargeted mass spectrometry (MS) strategy. In vitro metabolic dependencies were evaluated using 2-deoxy glucose (2-DG) treatment or glucose/glutamine nutrient limitation. RESULTS: Here we demonstrate that co-occurring KRAS mutation/LKB1 loss in NSCLC cells allowed efficient exploitation of glycolysis and oxidative phosphorylation, when compared to cells with each single oncologic genotype. The enhanced metabolic activity rendered the viability of cells with both genetic lesions susceptible towards nutrient limitation. CONCLUSIONS: Co-occurrence of KRAS mutation and LKB1 loss in NSCLC cells induced an enhanced metabolic activity mirrored by a growth rate vulnerability under limited nutrient conditions relative to cells with the single oncogenetic lesions. Our results hint at the possibility that energy stress induced by calorie restriction regimens may sensitize NSCLCs with these co-occurring lesions to cytotoxic chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0954-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6280460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62804602018-12-10 Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach Caiola, Elisa Falcetta, Francesca Giordano, Silvia Marabese, Mirko Garassino, Marina C. Broggini, Massimo Pastorelli, Roberta Brunelli, Laura J Exp Clin Cancer Res Research BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also have deletions or inactivating mutations in the serine/threonine kinase 11 (LKB1) gene. Loss of LKB1 on a KRAS-mutant background may represent a significant source of heterogeneity contributing to poor response to therapy. METHODS: Here, we employed an integrated multilevel proteomics, metabolomics and functional in-vitro approach in NSCLC H1299 isogenic cells to define their metabolic state associated with the presence of different genetic background. Protein levels were obtained by label free and single reaction monitoring (SRM)-based proteomics. The metabolic state was studied coupling targeted and untargeted mass spectrometry (MS) strategy. In vitro metabolic dependencies were evaluated using 2-deoxy glucose (2-DG) treatment or glucose/glutamine nutrient limitation. RESULTS: Here we demonstrate that co-occurring KRAS mutation/LKB1 loss in NSCLC cells allowed efficient exploitation of glycolysis and oxidative phosphorylation, when compared to cells with each single oncologic genotype. The enhanced metabolic activity rendered the viability of cells with both genetic lesions susceptible towards nutrient limitation. CONCLUSIONS: Co-occurrence of KRAS mutation and LKB1 loss in NSCLC cells induced an enhanced metabolic activity mirrored by a growth rate vulnerability under limited nutrient conditions relative to cells with the single oncogenetic lesions. Our results hint at the possibility that energy stress induced by calorie restriction regimens may sensitize NSCLCs with these co-occurring lesions to cytotoxic chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0954-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-04 /pmc/articles/PMC6280460/ /pubmed/30514331 http://dx.doi.org/10.1186/s13046-018-0954-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Caiola, Elisa Falcetta, Francesca Giordano, Silvia Marabese, Mirko Garassino, Marina C. Broggini, Massimo Pastorelli, Roberta Brunelli, Laura Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
title | Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
title_full | Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
title_fullStr | Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
title_full_unstemmed | Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
title_short | Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
title_sort | co-occurring kras mutation/lkb1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/ https://www.ncbi.nlm.nih.gov/pubmed/30514331 http://dx.doi.org/10.1186/s13046-018-0954-5 |
work_keys_str_mv | AT caiolaelisa cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT falcettafrancesca cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT giordanosilvia cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT marabesemirko cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT garassinomarinac cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT brogginimassimo cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT pastorelliroberta cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach AT brunellilaura cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach |